The FDA granted Biogen Idec orphan-drug status and accelerated review of its leukemia drug, lumiliximab, for treating the relatively rare chronic lymphocytic leukemia. The drug is in a Phase III trial comparing its use in combination with chemotherapy and the firm's Rituxan against just the combination of Rituxan and chemotherapy.

Related Summaries